CW-3308

• Description :

  CW-3308 is an orally effective PROTAC that selectively targets BRD9 and is expected to be used to inhibit synovial sarcoma, rhabdomyoma, and other BRD9-dependent human diseases. CW-3308 is composed of PROTAC target protein ligand Naphthyridin-Me-dimethoxybenzene-COOH (HY-159596) (red part), Linker 3-Azaspiro[5.5]undecane-9-methanol (HY-159598) (black part), E3 ubiquitin ligase ligand Thalidomide-methylpyrrolidine (HY-159597) (blue part), where the conjugate of E3 ubiquitin ligase ligand + linker is Thalidomide-pyrrolidine-C-azaspiro (HY-159599) [1].

• UNSPSC :

  12352005

• Target :

  Epigenetic Reader Domain; PROTACs

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; PROTAC

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cw-3308.html

• Purity :

  99.54

• Solubility :

  DMSO : 4.17 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=C4C(CN(CC(CC5)CCC65CCN(C(C7=C(OC)C=C(C(C8=CC=NC=C98)=CN(CC)C9=O)C=C7OC)=O)CC6)C4)=C3)=O

• Molecular Formula :

  C45H48N6O8

• Molecular Weight :

  800.90

• References & Citations :

  [1]Wang C, et al. Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9. J Med Chem. 2024 Aug 22;67 (16) :14125-14154.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [3055592-99-6]